Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Updating our model generates a valuation of £190.3m, equivalent to 76.6p
(74.4p fully diluted) vs £181.5m and 73.1p (71.3p fully diluted) previously.
An initial examination by
the Patent Office supports the patentability of MED3000 and forms the basis of a
Patent Cooperation Treaty (PCT) application filed in October 2020. The PCT
currently has 153 contracting countries, which means that management (and its
commercial partners) have until Q222 to decide in which countries it will seek
patents.
Liberum see Med3000 being launched commercially in H2.
That is very encouraging
James Barder, Chief Executive of Futura Medical, commented: "Futura has achieved major milestones in terms of securing partnering for the development and commercialisation of MED3000 in China and South East Asia in a deal structured to capture significant long-term value, as well as the EU Notified Body's recommendation to certificate MED3000 for Class 2B approval as a medical device for ED treatment under the European Medical Device Regulations."
"The Company is well positioned to deliver further positive news through 2021 especially around commercialisation of MED3000 and our objective to deliver a long term and sustainable revenue for shareholders."
" Futura's commercialisation collaborations"
looking forward to that
liambooth who has already been caught lying is now claiming he knows more than the world leading Erectile dysfunction experts.
He is also pretending to be different people
ok liam why don't you simply report yourself to the FCA for market abuse?
All formulations tested in FM57, including MED3000, have demonstrated positive and statistically significant efficacy results against baseline data together with excellent safety profile. MED3000 will be of high interest to the Medical Community for those patients who are seeking a very rapid onset of action and a very low side-effect profile. It will likely find use in the substantial number of patients, especially those with ED of a mild to moderate nature and those patients who are contraindicated for use with existing products.
Dr Yacov Reisman
Consultant Urologist and past president of the European Society of Sexual Medicine
Again directly contradicts your blatant attempt at putting out misinformation
The efficacy of MED3000 is remarkable and approaches the efficacy of current first line therapy but with significantly lower adverse events. With topical application, it will be of particular appeal to patients who want a fast onset of action. Lack of drug interactions with prescription products will enable the product to be used with other medications such as nitrates and other cardiovascular drugs. It can also be used in conjunction with other ED products to improve overall efficacy to patients. As such MED3000 will be of great interest to the medical community.”
Professor David Ralph
Consultant Urologist at University College London and past president of the European Society of Sexual Medicine
He like most other people would strongly disagree with your misinformation
You have posted 100 negative inaccurate defamatory statements about Futura and then insult everyone's intelligence by then stating you are a shareholder.
You are doing what you are accusing Futura of doing.
I guess that comes back to the old saying it takes one to know one.
You have been threatening others which means you already lost the argument.
Just tell the truth
You are posting lies again,a little odd for someone who is threatening others with reporting to the FCA for market abuse the co did acknowledge shelf life issues.
Med3000 is directly addressing a clinical condition
You are clueless
The other very important point I wan to make is that I tried the condom numerous times.
It was incredible in that it not only provided a firmer erection with the effect of one's part looking larger,the ejaculation was extremely intense.
The fact that Med3000 was able to achieve similar effects without the GTN tell me this will absolutely fly off the shelves and I shall be first in line to get some
You keep comparing apples with oranges.The condom was tainted by shelf life issues.Meaning that by the time the product got to the store it only had a couple of months shelf life left.
The upside of that is the co has gained huge knowledge about things such as shelf life.
The other point you are clearly blind to is the market sizes.
When Futura realised that an ED product was directly addressing a marketplace worth almost $6 billion a year they threw all their weight behind that product.
It was a strategic decision that decided to focus on a market that was multiples higher than the condom would ever manage to achieve.
Now here we are with EU approval now achieved and the CE mark being received within the next 45 days or so.
The beauty of a licensing business is it is really simple. Futura imply collect royalties which go straight to the bottom line.
The point being if the EU market alone is worth over 100p it is not hard to realise the shares could be worth many times the current price.
With sales in the Eu alone expecte to reach £280 million a year and a 20% royalty that is £56 million a year to Futura.
On a p/e of 10 that is a market cap well over 100p just on the EU sales of Med3000.
Then of course there is the rest of the world.
Interesting thought
19 March 2021
"In conjunction with the regulatory processes, Futura has been working with retained specialised corporate advisers on active commercial discussions with potential licensing and marketing partners.
Following the Company's recent announcement of a Joint Collaboration agreement for the China and the South East Asia region, partnering discussions for other countries continue in line with the agreed process being managed by Futura's corporate advisers. The Company has now received initial offers from a number of parties and believes the EU approval of MED3000 will assist the Company in its objective of delivering long-term, sustainable value through the licensing of MED3000."
Lol
When market makers have sold stock they don't own they bring the price down to try and attract sellers.
Then if that doesn't work the dirty tricks book comes out.
If Futura come out with something positive on wednesday they will be f"cked hence the jiggerypokery.
"MED3000 shows clinical trial efficacy results that are similar to those of Cialis® 5mg."
Proof is in the pudding.
You are right he/it/they have massively increased their intensity as we approach results day
Are barking up the wrong tree as liambooth/ig index/or market maker says they just need to apply ky jelly
You are trivialising what is a major issue for millions,you should be ashamed of yourselves.
Do you honestly think that none of the urologists have tried to see if any of those work?Or that any of their millions of patients have said hey doc I tried some KY and no longer have an ED problem.
Come on this kindergarten stuff